Cannabinoids for Parkinson's and Dementia in Older Adults: Promising Biology, Almost No Clinical Proof | Research

The takeaway

Preclinical evidence for CBD's neuroprotective effects in Parkinson's and Alzheimer's is compelling, but older adults are already using cannabis off-label despite the near-absence of clinical trial data.

Older adults with neurodegenerative conditions considering cannabis, or their caregivers and physicians.

What the researchers found

This review confronted a growing clinical reality: older adults with Parkinson's disease and dementia are increasingly using cannabinoids, but the evidence supporting this use is almost entirely preclinical. In the lab, CBD showed anti-amyloidogenic (reduces Alzheimer's-associated protein buildup), antioxidative, anti-apoptotic, anti-inflammatory, and neuroprotective effects. THC also showed neuroprotective properties in some models.

In clinical practice, patients were using cannabis for Parkinson's tremor, non-motor symptoms, anxiety, and sleep. For dementia, cannabis was being used to manage agitation and other responsive behaviors. Some clinicians considered cannabinoids an alternative when first-line treatments failed.

But the review was explicit: strong evidence from clinical trials was scarce for most indications. The gap between preclinical promise and clinical proof was wide. And age-related changes in the endocannabinoid system could alter how older adults respond to cannabinoids in ways that haven't been studied.

Why it matters

The population most likely to have neurodegenerative disease — older adults — is also the population most vulnerable to drug interactions and side effects, and the population least represented in cannabis research. This review highlighted a troubling pattern: patients and some clinicians were already treating Parkinson's and dementia with cannabis based on preclinical data and anecdotal reports, while the clinical trials that would confirm or refute benefit barely existed.

The age-related ECS changes add another concern. If the endocannabinoid system functions differently in a 75-year-old brain compared to a 25-year-old brain (as limited evidence suggests), dosing and effects could be unpredictable in exactly the population using it.

The numbers in context

• CBD preclinical effects: anti-amyloidogenic, antioxidative, anti-apoptotic, anti-inflammatory, neuroprotective

• Clinical uses (off-label): PD tremor, non-motor symptoms, anxiety, sleep, dementia agitation

• Clinical trial evidence: scarce for most indications

• Age-related ECS changes may alter cannabinoid response in older adults

How the study worked

Narrative review of preclinical and clinical evidence for cannabinoid use in Parkinson's disease and dementias, with particular attention to age-related changes in the endocannabinoid system. Published in Brain Sciences.

Who was studied

Review of cannabinoid use in aging populations with neurodegenerative disorders.

What this study cannot tell us

Narrative review without systematic methodology. Preclinical findings in animals and cell culture have poor translation rates to human neurodegenerative disease. Off-label use patterns are based on surveys and case reports, not controlled studies. Does not address the interaction between cannabinoids and common medications in older adults (polypharmacy). Age-specific pharmacokinetic data is extremely limited.

How to read the evidence

Narrative review finding strong preclinical rationale but near-absent clinical evidence for most neurodegenerative indications.

When this study was published

Published in 2022. Clinical trials of cannabinoids in neurodegenerative disease remain limited but are slowly increasing.

The bigger picture

Cannabis use among seniors is the fastest-growing demographic segment. This review showed the medical establishment is behind: patients are already using cannabinoids for neurodegenerative conditions, but the evidence base consists mainly of cell culture and animal studies. The ethical tension — between patients' right to try available options and the medical obligation to recommend evidence-based treatments — is acute in this space.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Should clinicians support off-label cannabis use for neurodegeneration when clinical evidence is minimal?
How do age-related ECS changes affect cannabinoid dosing and safety in seniors?
Which neurodegenerative indications are closest to having adequate clinical trial evidence?

Common questions

Can cannabis help with Parkinson's disease?

Patients report using it for tremor, anxiety, and sleep, and some lab evidence supports neuroprotective effects. But clinical trial evidence is almost nonexistent. The honest answer is we don't know yet.

Is cannabis safe for older adults?

That's understudied. Age-related changes in the endocannabinoid system may alter effects, and drug interactions are a major concern for older adults on multiple medications. Caution is warranted.

Read the original research

Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.

Brain sciences, 12(12)

Brain Sciences is a peer-reviewed journal focusing on neuroscience and related fields.

View on PubMed ↗Publisher’s paper ↗

Citation

Costa, Alana C; Joaquim, Helena P G; Pedrazzi, João F C; Pain, Andreia de O; Duque, Gustavo; Aprahamian, Ivan. (2022). Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.. Brain sciences, 12(12). https://doi.org/10.3390/brainsci12121596